The Delhi High Court’s decision in Intra-Cellular Therapies, Inc. v. The Controller of Patents [C.A.(COMM.IPD-PAT) 24/2023], provides significant guidance on novelty, inventive step and the enhanced efficacy requirement under Section 3(d) of the Patents Act, 1970. The judgment is particularly relevant to pharmaceutical inventions involving modifications of known compounds and the evidentiary burden required to […]